news
Celyad gets patent for TCR-deficient CAR T-cell method
2 March 2016 | By Victoria White
The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
List view / Grid view
T cells
article
Directing a weaponised attack on cancer with Natural Killer Receptor T-Cells
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
news
Studies suggest major role for Regen’s NR2F6 target in controlling key immune functions
18 February 2016 | By Victoria White
The results demonstrate that suppression of NR2F6 in T-cells results in increased expression of key immune stimulatory proteins IL-17 and IL-18...
news
‘Extraordinary’ t-cell cancer therapy results generate excitement
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
news
Microptosis could present an antimicrobial drug development opportunity
20 January 2016 | By Victoria White
Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
news
Scientists design new CAR architecture with switch-on system
12 January 2016 | By Victoria White
A new study describes the design of a CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions...
news
Project launched for CAR-T cell immuno-oncology therapy development
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
news
AIC649 shows potential to induce functional cure in preclinical HBV study
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
news
Cellectis files clinical trial application for UCART19 in leukaemia
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
news
Trial of CAR T-cell therapy in head and neck cancer starts
8 December 2015 | By Victoria White
Doctors are harnessing patients’ own immune systems in a pioneering trial taking place in London in an effort to find a new effective treatment for resistant head and neck cancer...
news
Adaptimmune and Universal Cells in T-cell therapy collaboration
1 December 2015 | By Victoria White
With Universal Cells’ proprietary gene editing technology, Adaptimmune intends to develop affinity enhanced donor T-cells...
news
Celyad awarded US patent covering allogeneic human primary T-Cells
26 October 2015 | By Victoria White
The US 9,181,527 Celyad Allogeneic Patent significantly strengthens Celyad’s patent portfolio in the CAR T-Cell field...
news
Nektar submits IND for NKTR-214 to treat solid tumours
8 October 2015 | By Victoria White
NKTR-214 is a CD122-biased immune-stimulatory cytokine that is designed to stimulate the expansion and maintenance of CD8-positive effector T-cells...
news
apceth and University of Cologne to join forces on combination cellular immunotherapies for cancer
10 July 2015 | By Victoria White
apceth is to partner with the University of Cologne to combine technologies and expertise, on the development of immunotherapies for solid tumours...
news
Didehydro-Cortistatin A reduces HIV reactivation rate
9 July 2015 | By Victoria White
Scientists have shown that didehydro-Cortistatin A reduces residual levels of HIV virus from dormant cells, establishing a near-permanent state of latency...
